Clinical Trial Detail

NCT ID NCT02942095
Title Study of Ixazomib and Erlotinib in Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

pancreatic ductal adenocarcinoma

lung non-small cell carcinoma

Therapies

Erlotinib + Ixazomib

Age Groups: senior adult

No variant requirements are available.